GFAP and amyotrophic lateral sclerosis: Also, microglial density and microglial activation measured using immunostaining for glial fibrillary acidic protein (GFAP) and CD6, show an increase in patients with ALS and FTD and correlate well with synaptic, axonal, and neuronal loss and faster motor and extra-motor disease progression (119–121).